Latest reporting
Latest in Drug Discovery & Research
AI Meets the Lab Bench: Anthropic Bets $1 Million That Claude Can Design Real Proteins
New competition will experimentally test over 5,000 AI-generated protein designs, building on prior work that achieved a 26.8% success rate in creating functional binders.
Claude AI Slashes Protein Design Costs 100-Fold While Autonomously Rewriting Drug Discovery Code
Anthropic's foundation model optimized 36 biomolecular AI packages in under four weeks, achieving 4x speed gains and enabling therapeutic design for $150 instead of $10,000 per target.
Pharma Giant Novo Nordisk Taps Third AI Partner in Six Months as Drug Discovery Race Intensifies
Anthropic's Claude Science models join OpenAI and AWS in Novo's accelerating push to embed artificial intelligence across research workflows.
The $300 Billion Problem: How AI Could Redesign Clinical Trials From the Ground Up
A new framework published in Nature Reviews Bioengineering maps out how validated AI tools—from digital twins to agentic systems—could slash trial costs and timelines while maintaining regulatory rigor.
DeepMind Cracks the 98% Problem: Free AI Atlas Maps Every Possible Human DNA Mutation
Google's AlphaGenome Atlas delivers precomputed predictions for 9 billion genetic variants, focusing on the regulatory \"dark matter\" that controls gene expression and has long eluded clinical interpretation.
IQVIA Promises to Slash Clinical Trial Startup Times by One-Third Using AI Platform
Healthcare giant unveils predictive development system claiming 33% faster study launches and 1.7x patient recruitment boost through automation and machine learning.
Machine Learning Cracks the Mitochondrial Code: Five New Drug Targets Emerge for Alzheimer's Treatment
Insilico Medicine's AI platform identifies blood-detectable biomarkers and novel therapeutic pathways by analyzing mitochondrial dysfunction across multiple neurodegenerative diseases.
Federal Government Bets $35 Million on AI to End Diagnostic Odysseys for 350 Million Rare Disease Patients
UNC and Emory will build the world's largest rare disease data repository to train artificial intelligence models capable of identifying conditions that currently take years to diagnose.
Clinical Trial AI Delivers 82-Fold Return in Tufts Economic Model, But Humans Still Hold the Reins
New analysis quantifies up to $21 million in value from Medable's monitoring agent for phase 3 oncology trials, establishing the first major ROI benchmark as the industry moves from pilot programs to production deployment.
DeepMind Alumni's AI Biotech Lands Third Major Cancer Data Deal in Five Months
Bioptimus secures access to 1,750+ UK colorectal cancer patient profiles as it races to build a 100,000-specimen foundation model for precision oncology.
Claude AI Outperforms Human Scientists in Protein Design Competition, Validating 354 Functional Binders
Anthropic's general-purpose AI achieved hit rates up to 35% in lab-validated protein engineering tests—more than double the industry standard—while analyzing complex chemistry data in minutes instead of days.
The Patent Paradox Threatening Billions in AI-Discovered Drugs
As artificial intelligence designs novel therapeutics with minimal human input, U.S. patent law's human-inventor requirement is creating legal uncertainty that could invalidate exclusivity rights for an entire generation of AI-developed medicines.
AI Agent Designs 354 Protein Binders in 48 Hours, Doubling Industry Success Rates
Anthropic's autonomous models orchestrated existing computational tools to generate high-affinity binders across oncology targets, achieving hit rates up to 35% compared to a 10-15% field norm.
The Validation Gap: Why AI-Designed Antibodies Just Hit Their First Real-World Reality Check
A landmark Nature Biotechnology benchmark reveals wildly inconsistent performance across 29 organizations' AI platforms, exposing the fragile evidence base beneath computational drug discovery's regulatory future.
Digital Pathology Alliance Aims to Streamline AI-Powered Cancer Diagnostic Development
Imagene AI's integration with Proscia's platform creates end-to-end pathway for pharmaceutical companies to develop companion diagnostics from discovery through clinical deployment.
AI Slashes Cancer Drug Development Costs by 90%, Biotech Claims—But Can the Model Scale?
Lantern Pharma reports its artificial intelligence platform reduces early-stage oncology development costs to $2-3 million per program, a fraction of traditional industry spending, while spinning out the technology as a commercial software business.
Drug Discovery's New Speed Limit: How AI Slashed a Decade-Long Process to 18 Months
Insilico Medicine's breakthrough pulmonary fibrosis candidate reached Phase 2 trials in record time, forcing clinical operators to rethink procurement, trial partnerships, and patient engagement strategies.
AI Monitoring Agent Delivers 82x ROI and $21 Million Gains in Cancer Drug Trials, Tufts Analysis Finds
First evidence-based financial modeling of agentic AI in drug development shows Medable's clinical monitoring system accelerates oncology programs by 10 weeks while slashing on-site monitoring costs.
AI Platform Delivers Eye Drop Candidate That Triples Efficacy Against Leading Cause of Vision Loss
Insilico Medicine's generative chemistry AI produces ISM9077 in half the traditional timeline, targeting dry AMD and inflammatory eye diseases with superior preclinical performance.
The $8.9 Billion Question: Why AI Drug Discovery Still Has Nothing on Pharmacy Shelves
Three years of sliding approval timelines expose a critical gap between artificial intelligence's preclinical promise and the regulatory infrastructure needed to bring AI-discovered medicines to patients.
Scientists Use AI to Engineer Living Viruses From Scratch, Raising Biosecurity Alarms
Stanford and Arc Institute researchers deployed an AI model to create 16 functional bacteriophages never seen in nature, demonstrating breakthrough genomic design capabilities that experts warn could be weaponized.
The Manufacturing Gap Threatening AI Drug Discovery's Promise
As AI-designed therapeutics reach human trials, venture capital firms warn that experimental validation and production capacity—not computational power—now determine which digital molecules become real medicines.
From Black Box to Bedside: How AI Is Finally Solving Cancer Immunotherapy's Biggest Prediction Problem
New multimodal AI models are outperforming traditional biomarkers in predicting which patients will respond to immunotherapy, potentially ending the era of trial-and-error treatment selection.
AI Brain Mapping Reveals Why Alzheimer's Tau Proteins Spread Differently at Each Disease Stage
New multi-layer network model pinpoints how toxic proteins travel through distinct brain pathways as dementia progresses, opening doors to precision-timed therapies.
How One Cloud Platform Is Solving AI's Biggest Genomics Problem
DNAnexus positions itself as the critical infrastructure layer connecting massive genomic datasets with artificial intelligence-driven precision medicine applications.
Why Biotech's AI Revolution Is Finally Moving Beyond the Lab and Into the Clinic
Nine companies reveal how artificial intelligence is tackling drug development's 90% failure rate by predicting which therapies will actually work in patients, not just in petri dishes.
Clinical Trial AI Gets a Major Overhaul as Medidata Bets on Platform Integration Over Point Solutions
New embedded AI layer aims to solve biopharma's fragmented tooling problem as industry leaders admit 71% of current AI deployments fall short of expectations.
AI Scientists Are Now Running Their Own Labs: Stanford Unveils Autonomous Research Agents That Generate Hypotheses and Write Papers
Stanford Medicine researchers deploy AI agents that function as virtual lead investigators, conducting biomedical research from hypothesis generation through manuscript preparation with minimal human oversight.
Pharma's Computational Arms Race Heats Up as Bristol Myers Squibb Builds Supercomputing Drug Discovery Powerhouse
Bristol Myers Squibb partners with Nvidia to deploy what it claims will be the life sciences industry's most powerful AI infrastructure, signaling an escalating battle for computational supremacy in drug development.
Diagnostic Giant Labcorp Enters AI Drug Discovery Race With Decades of Patient Data as Secret Weapon
Laboratory testing leader leverages billions of clinical test results spanning years to challenge specialized AI drug discovery firms and reshape pharmaceutical research.